LifeVantage Corporation has extended its MindBody GLP-1 System into international markets. The system’s success in the US has been credited with the company’s recent 49% year-over-year increase in revenue during the second quarter of the fiscal year.
Known as the MB System internationally, the GLP-1 products are now available in Japan and will be available to customers in Australia, New Zealand, Europe, the UK, Mexico and Thailand on April 25. Taiwan and the Philippines can expect the MB System to launch early this summer, with Canada launching in late 2025.
“Consumers worldwide are seeking sustainable health solutions that go beyond short-term, unsustainable weight management,” said Steve Fife, LifeVantage President and CEO. “The MB System works harmoniously with the body, empowering individuals to naturally enhance their metabolic health in alignment with their lifestyle and wellness objectives.”
LifeVantage stated that the global GLP-1 pharmaceutical market is projected to grow at a CAGR of 17.5% over the next five years to reach a valuation of $156.7 billion.
“The research that is emerging on all the positive health benefits of the GLP-1 hormone continues to excite us,” said Lisa Barnes, LifeVantage Vice President of Research & Development and Regulatory. “From gut and digestive benefits, heart and cardiovascular benefits, and the health of other critical organs like the kidneys and liver, GLP-1 is a hormone essential for our longevity and vitality. We are so proud of this product and the clinically shown efficacy in activating the body’s own production of the hormone.”
